ClinicalTrials.gg
RecruitingNCT06943859Updated Oct 20, 2026

Ketamine for Opioid Use Disorder

A Phase 2 interventional study of Treatment with Ketamine and Treatment with Very Low Dose Ketamine in Opioid Use Disorder, sponsored by University of Maryland, Baltimore. Recruiting at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-20.

Sponsored by University of Maryland, Baltimore · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Feb 2026; still recruiting 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 16 studies in Opioid-Related Disorders by University of Maryland, Baltimore — 6 open to participants now, 8 under way, 2 of them phase 3. Opioid-Related Disorders · University of Maryland, Baltimore.

Planned enrollment
7th of 15
50 · median 50
Started
2026
with 2 others
Phase 2
5 of 16
3 open now
Registered
13th of 16
by date

Among the 16 studies in Opioid-Related Disorders by University of Maryland, Baltimore, this one is the 7th largest by planned enrollment of the 15 interventional ones that give a count, is one of 3 that started in 2026, is one of 5 in phase 2, and was the 13th registered.

Opioid-Related Disorders

1,476 studies on the registry are indexed under Opioid-Related Disorders; 293 are open to participants now.

Browse Opioid-Related Disorders studies →

Open to participants now

6 of the 16 studies in Opioid-Related Disorders by University of Maryland, Baltimore are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 213 Opioid-Related Disorders studies recruiting now, 123 (58%) set no upper age limit and 76 (36%) stop at 75 or younger; 14 take children under 18; 53 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Opioid-Related Disorders by University of Maryland, Baltimore, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if ketamine works to reduce craving for opioids in adults enrolled in methadone treatment for opioid use disorder. The main questions it aims to answer are:

  • Does ketamine reduce craving for opioids in patients with opioid use disorder?
  • Does ketamine reduce symptoms of opioid withdrawal such as depression, pain, and poor sleep quality?
  • Do patients who take the low dose ketamine stay in methadone treatment longer, and/or have better treatment outcomes than those given the very low dose?

Researchers will compare two low doses of ketamine to see if ketamine works to reduce craving for opioids in adults enrolled in methadone treatment for opioid use disorder.

Participants will:

  • Be given a low dose or a very low dose of ketamine 4 times over a period of 2 weeks
  • Visit with the study team one week prior to the first ketamine session, one week following the last ketamine session, at 30 days following the final ketamine session, and 90 days following the final ketamine session for checkups and tests
03

Conditions studied

  • Opioid Use Disorder

Keywords

  • opioid use disorder
  • ketamine
  • craving
  • treatment adherence
  • methadone
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 18 to 65 years old
  2. Fulfillment of /ICD-10 criteria for moderate-to-severe opioid use disorder
  3. Acceptance into methadone treatment for opioid use disorder at the time of screening.
  4. Adherence to lifestyle requirements for participation.
  5. Self-reported craving greater than or equal to 20 out of 100 for opioids at any point in the past week at time of screening
  6. Positive UDS for opioids or self-reported illicit opioid use in the past three months at time of screening

Exclusion criteria

Exclusion Criteria

  1. Pregnant and/or breastfeeding.
  2. **Stage 2 Hypertension, defined by a systolic blood pressure (SBP) > 140 mmHg or a diastolic blood pressure (DBP) > 90 mmHg.
  3. Abnormal oxygen saturation or abnormal heart rate (i.e. O2 saturation \<95%, or HR \<60 or >100bpm
  4. abnormal findings for which study participation is deemed unsafe.
  5. Severe mental illness or psychiatric disorder for which study participation is deemed unsafe (except for depression, PTSD, and substance use disorder).
  6. **/AST > 3 x (ULN), ALP 2 x ULN, or total > 1.5 x ULN.
  7. History of to ketamine.
  8. Suicidal ideation with a plan or intent or suicidal behaviors as reflected in Columbia-Suicide Severity Rating Scale (C-SSRS).
  9. Recent homicidal ideation or violent behaviors.
  10. Concomitant daily use of medications with significant CYP2B6 and inhibition or induction effects that can interfere with metabolism of ketamine.
  11. Advanced cardiopulmonary disorders, including stroke, cardiac arrest, and myocardial infarction in the past year
  12. History of aneurysmal vascular disease or dissection (including thoracic and abdominal aorta, intracranial, and peripheral arterial vessels) or arteriovenous malformation.
  13. **Clinically significant abnormalities.
  14. Current significant use (>3 days/week) of barbiturates, sedative hypnotics, benzodiazepines, ketamine, or PCP (prescribed or illicit).

    • NOTE: Due to time constraints in the study design, these exclusion criteria do not need to be met before the initial consent to participate. This criterion only needs to be established prior to the first ketamine session. This will allow us to enroll participants as soon as possible, giving more time and flexibility to complete the baseline assessments before the first ketamine session. Individuals that are initially enrolled and subsequently do not qualify due to severe hepatic impairment will be considered screen failures and withdrawn from the protocol. Because repeated ketamine administration is associated with hepatobiliary dysfunction (most often a cholestatic pattern) we will also obtain a follow up LFT within 30 days of the final ketamine session.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Treatment with Ketamine

    Individuals will receive four doses spaced 1-6 days apart of 0.75mg/kg of intramuscular ketamine (n=25) over a period of two weeks.

    Drug: Treatment with Ketamine

  • Active comparator
    Treatment with Very Low Dose Ketamine

    Individuals will receive four doses spaced 1-6 days apart of an intramuscular ketamine (0.1mg/kg) (n=25) over a period of two weeks.

    Drug: Treatment with Very Low Dose Ketamine

Interventions

  • DrugTreatment with Ketamine

    Drug page: KetamineStudies of KetamineKetamine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Participants will receive four doses of ketamine spaced 1-6 days apart of 0.75 mg/kg intramuscular ketamine (n=25) for two weeks (first ketamine session must occur no later than 28 days post-intake). Individuals will be monitored for two hours post-dose by a clinician.

  • DrugTreatment with Very Low Dose Ketamine

    Participants will receive four doses of very low dose ketamine (0.1mg.kg) (n=25) spaced 1-6 days apart for two weeks (first ketamine session must occur no later than 28 days post-intake). Individuals will be monitored for two hours post-dose by a clinician.

06

What researchers measure

Primary outcomes

  1. Tonic craving (FORCAST) total scores

    Faceted Opioid Research Craving Assessment for Substance use Treatment (FORCAST): A 26-item assessment of tonic craving that the person reports having felt over the prior one or two weeks. Participants indicate how much they disagree or agree with each statement on a scale that ranges from 0-6, with 0 representing "strongly disagree", 3 representing "neither agree nor disagree", and 6 representing "strongly agree". Higher scores indicate higher levels of craving. The minimum score is 0, and the maximum scores for each of the subscales are as follows: Preoccupation: 24 Negative Reinforcement: 30 Positive Reinforcement: 24 Motivation: 30 Lack of control: 24 Uneasiness: 24 Maximum total score for all subscales = 156

    Time frame: Collected at 7 days pre- and post-ketamine, 30-, and 90-days post-final ketamine session

Secondary outcomes

  1. Severity of depression symptoms

    Montgomery-Asberg Depression Rating Scale (MADRS): a 10-item questionnaire of depression severity. The total score ranges from 0-60, with scores of 0-6 considered normal (non-depressed), 7-19 indicative of mild depression, 20-34 indicative of moderate depression, and 35-60 indicative of severe depression. Item 10 on the instrument will be used to monitor any changes in suicidal ideation throughout the trial.

    Time frame: Completed at 7 days pre- and post-ketamine, 30-, and 90-days post final ketamine session

  2. Cue-induced craving scores

    Cue Reactivity Paradigm: our drug cue reactivity paradigm will be designed to elicit an acute craving state. We will present a series of opioid cue images continuously (total time \<5 min) via computer or tablet. Cues will be personalized based on each individual's drug use history as derived from baseline clinical assessments. For example, if a participant had no history of intravenous drug injection, we will not present opioid cue images containing injection paraphernalia like needles and instead will present images with opioid pills and/or powder. At the end of each one-minute session, participants will be asked to rate, on a scale of 1-10, "How much did you like the images you saw?", "How much do you want to use right now?", "How much do you want to avoid using right now?", "How much control do you feel you have over using right now" and "What is the maximum amount you would pay right now for a single dose of what you saw?"

    Time frame: Collected at 7 days pre- and post-ketamine, 7 days pre- and post ketamine, ketamine administration days, 30-, and 90-days post-final ketamine session

  3. Chronic pain ratings

    Graded Chronic Pain Scale (GCPS): a six-item instrument that evaluates chronic pain severity (intensity and impact on life activities).

    Time frame: Collected at 7 days pre- and post-ketamine, ketamine administration days, 30-, and 90-days post-final ketamine session

  4. Number of methadone doses received at 90 days post final ketamine session

    Study team will have access to clinic records to assess the number of methadone doses patients have received at 90 days post final ketamine session

    Time frame: Collected through 90 days post final ketamine session

  5. Sleep quality ratings

    Pittsburgh Sleep Quality Index (PSQI): A 19-item questionnaire assessing past-month sleep quality and disturbances. Seven component scores are generated: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping medication, and daytime dysfunction. The sum of scores for the 7 components yields one global score

    Time frame: PSQI collected at 7 days pre- and post-ketamine, 30-, and 90 days post-final ketamine session

  6. Insomnia Symptoms

    Insomnia Severity Index (ISI): A five-item measure of current (past two weeks, or since last study visit) insomnia symptoms.

    Time frame: Collected at 7 days pre- and post-ketamine, ketamine administration days, 30-, 90-days post-final ketamine session

  7. Sleep quality ratings on a Visual Analogue Scale (VAS)

    Modified Single Item Sleep Quality Scale (SQS): A self-administered questionnaire that incorporates a VAS delivered electronically. SQS directs the patient to rate the overall quality of sleep over a 7-day period (modified for our study to rate the overall quality of sleep the past night) on a scale of 1-10 considering how many hours of sleep they had, how easily they fell asleep, how often they woke up during the night (excluding bathroom trips), how often they woke up earlier than intended

    Time frame: SQS collected via daily optional EMAs through 7 days post final ketamine session, then every other day until 90 days post final ketamine session

  8. Scores on a holistic measure of recovery

    Substance Use Recovery Evaluator (SURE): A 21-item patient reported outcome measure of recovery from substance use disorder that has good face and content validity, acceptability and usability for people in recovery and is psychometrically valid.

    Time frame: Collected at 7 days pre- and post-ketamine, 30-, and 90 days post-final ketamine session

  9. Frequency of negative urine drug screens through 90 days post final ketamine session

    Study team will have access to clinic drug screenings through 90 days post-intake

    Time frame: collected through 90 days post final ketamine session

Other outcomes

  1. Decision making test performance (risk and ambiguity tolerance)

    Choice under risk and ambiguity (CRA) decision making task: On each trial, participants choose between a guaranteed $1 and a lottery. Each lottery has 2 possible outcomes: v or $0, where v ranges from $1.20 to $13.20. On half of the trials, v could be received with 1 of 3 known probabilities (p: 25%, 50%, or 75%); on the other half, the probability information is occluded and thus incompletely known (the ambiguity context). There are 3 levels of ambiguity: low (24% unknown), medium (50% unknown), and high (74% unknown). In reality, the true underlying probability in ambiguity trials is fixed at 50%. Different combinations of v, risk level, and ambiguity level are presented for 30 trials total. A modified utility model will be used which can extract the following parameters from participant decisions on these trials: * risk tolerance * ambiguity tolerance * choice stochasticity

    Time frame: collected weekly through 90 days post final ketamine session via optional EMAs

  2. Methadone dose (mg) at 90 days post final ketamine session

    Study team will have access to clinic records of methadone dose (mg) received by participant at 90 days post final ketamine session

    Time frame: collected through 90 days post final ketamine session

  3. OUD treatment outcomes at 6-, 9-, and 12 months post study enrollment

    Study team will have access to clinic records of methadone dose, number of methadone doses received, and frequency of negative drug screens though 12 months post study enrollment

    Time frame: collected through 6-, 9-, and 12 months post study enrollment

07

Study locations

1 of 1 sites recruiting
  • University of Maryland Addiction Programs and Affiliated Clinics
    Baltimore, Maryland 21201, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for Aug 2028, 30 months after the start.

Of 61 non-industry phase 2 interventional studies under Opioid-Related Disorders, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 55. This study's planned 30 months is below that.

Counting every sponsor, half of 68 studies reached it within 40 months; a quarter within 23 and three quarters within 55.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 9, 2025
First posted
Apr 24, 2025
StartActual
Feb 4, 2026
Primary completionEst.
Aug 31, 2028
CompletionEst.
Aug 31, 2029
Last update
Oct 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Site contacts
Changed at 1 site. See the sites
Show the site
  • University of Maryland Addiction Programs and Affiliated Clinics · Baltimore, United StatesContact a•••@som.umaryland.edu · •••3400→p•••@som.umaryland.edu · •••2814
Oct 20, 2026
Show all 1 update
  1. Oct 20, 2026
    Site contacts Changed at 1 site. See the sites
    Show the site
    • University of Maryland Addiction Programs and Affiliated Clinics · Baltimore, United StatesContact a•••@som.umaryland.edu · •••3400→p•••@som.umaryland.edu · •••2814

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06943859
Responsible party
Peter Manza (Assistant Professor, University of Maryland, Baltimore) — Principal investigator
First posted
Apr 24, 2025
Start date
Feb 4, 2026
Primary completion
Aug 31, 2028 (estimated)
Completion
Aug 31, 2029 (estimated)
Last update
Oct 20, 2026

Study contacts

Peter Manza, PhD
Contact
peter.manza@som.umaryland.edu
410-706-2814
Kynah Walston, MA
Contact
Kynah.Walston@som.umaryland.edu
443-974-7951
Peter Manza, PhD
principal investigator · University of Maryland, Baltimore

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ketamine

Start the discussion